Last reviewed · How we verify
Oral ecnoglutide tablet
At a glance
| Generic name | Oral ecnoglutide tablet |
|---|---|
| Also known as | GLP-1 analogue, XW004 |
| Sponsor | Sciwind Biosciences APAC CO Pty. Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (PHASE2)
- A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity (PHASE1, PHASE2)
- XW004 To Evaluate the Safety, Tolerability, PK, and PD of Oral Ecnoglutide Tablet in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral ecnoglutide tablet CI brief — competitive landscape report
- Oral ecnoglutide tablet updates RSS · CI watch RSS
- Sciwind Biosciences APAC CO Pty. Ltd. portfolio CI